Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy

- Streptozotocin(STZ)-induced diabetic neuropathy along with microglia activation.
- STZ up-regulates IL-1β, IL-3, IL-4, IL-6, IL-9, IL12p70, IL-17, IFNγ, sTNFRII.
- Minocycline increases antinociceptive factors IL-1alpha, IL-2, IL-10, sTNFRII.
- Minocycline reduces neuropathic pain, microglia activation and morphine effectiveness.

A single streptozotocin (STZ) injection in mice can induce significant neuropathic pain along with an increase in plasma glucose levels and a decrease in body weight. Seven days after the administration of STZ, an upregulation of C1q-positive cells was observed. Additionally, interleukins (IL-1beta, IL-3, IL-4, IL-6, IL-9, IL12p70, IL-17); proteins of the tumor necrosis factor (TNF) family, e.g., IFNgamma and sTNF RII, were upregulated. Chronic administration of minocycline increases antinociceptive factors (IL-1alpha, IL-2, IL-10, sTNFRII) in diabetic mice. Minocycline also reduces the occurrence of neuropathic pain and significantly potentiates the antiallodynic and antihyperalgesic effects of morphine.

132